Invitrogen™ Sapelizumab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Satralizumab (Enspryng), a humanized monoclonal antibody, is specifically designed to target and inhibit the interleukin-6 (IL-6) receptor. Interleukin-6 receptor alpha (IL-6Ra or CD126) is a critical component of the IL-6 signaling pathway, which plays a pivotal role in immune regulation, inflammation, and hematopoiesis. The gene for IL-6Ra is located on chromosome 1 at the p31 region. The structure of IL-6Ra includes an extracellular domain that binds IL-6, a transmembrane domain, and an intracellular domain that interacts with the signal transducer gp130, facilitating the activation of downstream signaling pathways. There are two forms of IL-6 signaling: classic signaling, which occurs when membrane-bound IL-6Ra (mIL-6Ra) forms a complex with IL-6 and gp130, primarily affecting immune cells and hepatocytes; and trans-signaling, which involves a soluble form of IL-6Ra (sIL-6Ra) and can act on a broader range of cells. Dysregulation of IL-6 and its receptor has been implicated in various inflammatory and autoimmune diseases, making them targets for therapeutic intervention.